BCM
IMMU

Bayesian Capital Management’s Immunomedics Inc IMMU Stock Holding History

Bayesian Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,500
Closed -$133K – 655
2017
Q1 		$133K Buy
+20,500
New +$104K 0.06% 370

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bayesian Capital Management's IMMU Position: Q2 2017 in Review

Bayesian Capital Management sold out of Immunomedics Inc (IMMU) in Q2 2017, closing a stake of 20,500 shares — an estimated $133K sold.

Bayesian Capital Management first reported a position in IMMU in Q1 2017 and held it in 1 quarter. The position peaked at $133K in Q1 2017. 130 funds tracked by Wall St. Rank hold IMMU as of Q2 2017.

  • Bayesian Capital Management reported no remaining Immunomedics Inc position as of Q2 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 20,500 Immunomedics Inc shares in Q2 2017, an estimated $133K.
  • Bayesian Capital Management first reported a position in Immunomedics Inc in Q1 2017 and held it in 1 quarter.
  • Bayesian Capital Management's Immunomedics Inc position peaked at $133K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2017.

Based on Bayesian Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.